Surgical Timing for Patients With Thyroid Eye Disease Treated With Teprotumumab: A Collaborative Multicenter Study
Our study suggests that while the rate of regression may not differ significantly, the severity, clinical impact, and need for additional surgery might be more pronounced for patients who have surgery more than 6 months after their last teprotumumab dose.
Authors
- Suzanne K. Freitag (ORCID: https://orcid.org/0000-0003-0887-1487)
- Andrea L. Kossler (ORCID: https://orcid.org/0000-0003-3110-1210)
- Sara Tullis Wester (ORCID: https://orcid.org/0000-0002-7289-0853)
- Carolina A. Chiou (ORCID: https://orcid.org/0000-0002-0169-9429)
- Raymond S. Douglas (ORCID: https://orcid.org/0000-0002-3435-8161)
- Shoaib Ugradar (ORCID: https://orcid.org/0000-0003-4479-3033)
- Hannah Walsh (ORCID: https://orcid.org/0000-0002-4591-5971)
- Kevin D. Clauss (ORCID: https://orcid.org/0000-0002-5534-8157)
- Benjamin I. Meyer (ORCID: https://orcid.org/0000-0002-0970-5854)
- Emanuil Parunakian (ORCID: https://orcid.org/0000-0001-7321-805X)
- Çigdem Yaşar (ORCID: https://orcid.org/0000-0003-0386-3613)
- Thomas E. Johnson
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- University of Miami (US)
- University of California, Los Angeles (US)
- Orbital Research (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmic Plastic and Reconstructive Surgery
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1097/iop.0000000000002839
- Citations
- 7
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.97